A third member of a prestigious FDA panel has resigned over the approval of a controversial new Alzheimer's drug

A third member of a prestigious FDA panel has resigned over the approval of a controversial new Alzheimer's drug

Business Insider

Published

Dr. Aaron Kesselheim said the agency's decision to approve Biogen's new drug "was probably the worst drug approval decision in recent US history."

Full Article